---
title: "GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280879865.md"
description: "Kailera Therapeutics and Alamar Biosciences have filed for U.S. IPOs. Kailera, focused on weight loss drugs, plans to list on Nasdaq under \"KLRA\" with its lead candidate, ribupatide, in Phase 3 trials. The company reported a $149M net loss in 2025. Alamar, specializing in proteomics, aims to list under \"ALMR\" and reported $74.2M revenue in 2025, with a narrowed net loss of $29.8M. Both companies are seeking to raise capital through their IPOs."
datetime: "2026-03-28T13:57:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280879865.md)
  - [en](https://longbridge.com/en/news/280879865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280879865.md)
---

# GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs


### Related Stocks

- [GRTX.US](https://longbridge.com/en/quote/GRTX.US.md)
- [NBSE.ESC.US](https://longbridge.com/en/quote/NBSE.ESC.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [CYTOF.US](https://longbridge.com/en/quote/CYTOF.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)